• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges 50 Points; US Durable Goods Orders Increase In April

    5/24/24 9:43:15 AM ET
    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Medicinal Chemicals and Botanical Products
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples
    Get the next $AKAN alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Friday.

    Following the market opening Friday, the Dow traded up 0.14% to 39,121.86 while the NASDAQ rose 0.39% to 16,801.18. The S&P 500 also rose, gaining, 0.35% to 5,286.08.

    Check This Out: Top 3 Health Care Stocks That May Crash In May

    Leading and Lagging Sectors

    Communication services shares jumped by 0.7% on Friday.

    In trading on Friday, health care shares rose by just 0.1%.

    Top Headline

    U.S. durable goods orders increased by 0.7% month-over-month in April compared to a revised 0.8% gain in March. However, markets were expecting for a 0.8% decrease.

    Equities Trading UP
                           

    • Akanda Corp. (NASDAQ:AKAN) shares shot up 103% to $4.8598. The international medical cannabis company implemented a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, according to a recent exchange filing.
    • Shares of Netcapital Inc. (NASDAQ:NCPL) got a boost, surging 63% to $0.2836 after jumping 15% on Thursday.
    • Better Choice Company Inc. (NYSE:BTTR) shares were also up, gaining 64% to $6.71.

    Equities Trading DOWN

    • Verastem, Inc. (NASDAQ:VSTM) shares dropped 59% to $5.05. The company announced that it initiated the rolling submission of a NDA to the FDA for accelerated approval of the combination of avutometinib and defactinib for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer.
    • Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) were down 47% to $0.78. Sensei Biotherapeutics presented clinical data from Phase 1 dose escalation study of SNS-101.
    • Genelux Corporation (NASDAQ:GNLX) was down, falling 39% to $2.79 after the company reported pricing of approximately $27.5 million underwritten offering of common stock and accompanying warrants.

    Also Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Financial Stocks Delivering High-Dividend Yields

    Commodities

    In commodity news, oil traded up 0.1% to $76.88 while gold traded up 0.2% at $2,340.80.

    Silver traded up 0.7% to $30.68 on Friday, while copper fell 0.4% to $4.7750.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX declined 0.4% and France's CAC 40 slipped 0.3%. Spain's IBEX 35 Index fell 0.9%, while London's FTSE 100 declined 0.4%.

    Producer prices in Spain declined by 6.6% year-over-year in April compared to an 8.2% fall in March. The manufacturing climate indicator in France declined to a reading of 99 in May. German economy grew by 0.2% quarter-over-quarter in the three months to March versus a 0.5% contraction in the prior period. Retail sales in the UK fell 2.3% month-over-month for April versus a revised 0.2% decline a month ago.

    Asia Pacific Markets

    Asian markets closed lower on Friday, with Japan's Nikkei falling 1.17%, China's Composite Index declining 0.88%, Hong Kong's Hang Seng Index falling 1.38% and India's S&P BSE Sensex falling 0.1%.

    The annual inflation rate in Japan eased to 2.5% in April versus 2.7%, while core consumer price index in Japan increased 2.2% year-over-year in April versus a 2.6% rise in the prior month.

    Economics

    U.S. durable goods orders increased by 0.7% month-over-month in April compared to a revised 0.8% gain in March. However, markets were expecting for a 0.8% decrease.

    Now Read This: Apple To Rally Over 47%? Here Are 10 Top Analyst Forecasts For Friday

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $BTTR
    $GNLX
    $NCPL

    CompanyDatePrice TargetRatingAnalyst
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    Genelux Corporation
    $GNLX
    10/21/2025$16.00Buy
    Lake Street
    Verastem Inc.
    $VSTM
    10/16/2025Overweight
    Cantor Fitzgerald
    Sensei Biotherapeutics Inc.
    $SNSE
    6/2/2025$5.00Buy
    H.C. Wainwright
    Verastem Inc.
    $VSTM
    4/10/2025$15.00Buy
    Jefferies
    Verastem Inc.
    $VSTM
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    Verastem Inc.
    $VSTM
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    Genelux Corporation
    $GNLX
    10/29/2024$8.00Buy
    Guggenheim
    More analyst ratings

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Conacher Lionel F. sold $1,086 worth of shares (635 units at $1.71) and bought $227,359 worth of shares (30,463 units at $7.46), decreasing direct ownership by 36% to 23,814 units (SEC Form 4)

    4 - Better Choice Co Inc. (0001471727) (Issuer)

    12/26/24 12:03:11 PM ET
    $BTTR
    Beverages (Production/Distribution)
    Consumer Staples

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

    Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251 Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net

    2/4/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

    Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers where clinical velocity is finally shattering historical benchmarks. With the FDA's 2026 framework explicitly prioritizing accelerated pathways for platforms showing superior objective response rates and durability[2], a select group of innovators is unlocking the immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ:ONCY), Pfizer (NYSE:PFE),

    1/30/26 10:19:00 AM ET
    $ONCY
    $PFE
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $6.88 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on

    1/12/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    SEC Filings

    View All

    SEC Form 8-K filed by Netcapital Inc.

    8-K - Netcapital Inc. (0001414767) (Filer)

    2/6/26 4:30:23 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Verastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    2/4/26 7:30:33 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GENELUX Corp (0001231457) (Filer)

    2/2/26 4:16:29 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paterson Dan sold $6,489 worth of shares (970 units at $6.69), decreasing direct ownership by 0.16% to 612,919 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    2/5/26 4:10:10 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Calkins Daniel was granted 16,665 shares, increasing direct ownership by 16% to 121,384 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/23/26 4:58:52 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Paterson Dan was granted 213,785 shares, increasing direct ownership by 53% to 613,889 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/23/26 4:57:26 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Leadership Updates

    Live Leadership Updates

    View All

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Financials

    Live finance-specific insights

    View All

    Netcapital Acquires Iverson Design Assets and Proprietary AI Design Technology Suite

    Accelerates Transformation into Tokenization and Digital Asset Platform BOSTON, MA, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)), a digital private capital markets ecosystem, today announced the acquisition of the assets of Iverson Design, LLC, a creative studio and developer of AI-powered design and visualization tools. Led by multimedia and AI designer Michael Iverson, the studio develops motion graphics, 3D product visualization, investor presentations, and immersive digital experiences. As part of the transaction, Michael Iverson joins Netcapital as Chief Design Director and Head of AI Experience. Under the agreement, Netcapital acquired Iverson Design's f

    1/6/26 4:22:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Netcapital Reports Second Quarter Fiscal 2026 Financial Results and Provides Corporate Update

    Expands offering beyond traditional securitiesEnhanced platform to enable private companies to raise capital on-line utilizing cryptocurrency and blockchain financingNewly appointed CEO Rich Wheeless to host business update conference call tomorrow at 10:00 a.m. ET BOSTON, MA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW, Netcapital)) (the "Company"), a digital private capital markets ecosystem, today announced financial results and provided corporate highlights for the second quarter of fiscal 2026 ended October 31, 2025. In addition, management plans to host a business update conference call tomorrow, December 16, 2025, at 10:00 a.m. ET. "Our platform serves t

    12/15/25 4:55:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Ended Q3 2025 with $137.7 million in cash and cash equivalents; with expected product revenue and exercise of cash warrants, Company cash runway would extend into the second half of 2026 Company to host a conference call and webcast today at 8:00 a.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical compa

    11/4/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BTTR
    $GNLX
    $NCPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care